Gold Cluster Drugs for Glaucoma Beyond Intraocular Pressure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical treatments for glaucoma primarily focus on reducing intraocular pressure, which is insufficient to prevent progressive optic nerve damage and retinal ganglion cell apoptosis, as evidenced by the continued worsening of optic nerve function despite controlled pressure, and no effective drugs exist to inhibit amyloid-beta (Aβ) aggregation that contributes to optic nerve damage.
Innovation Solution
The application of gold clusters (AuCs) with specific ligands, such as L-cysteine derivatives, to inhibit Aβ aggregation and protect optic nerve function, administered through oral, injection, or local eye drops, demonstrating efficacy in in vitro and animal models by reducing RGCs apoptosis and improving visual function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If intraocular pressure is reduced through clinical treatment, then the early predisposing factor for optic nerve damage is addressed, but progressive optic nerve damage and retinal ganglion cell apoptosis continue to worsen
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that can cross the blood-retina barrier and blood-brain barrier to directly act on retinal ganglion cells and optic nerve tissue. These compounds serve as mediators between systemic administration and the protected neural tissue, enabling neuroprotection independent of intraocular pressure control.
Solution Approach 2:
The patent changes the therapeutic approach from pressure-based treatment to molecular-based treatment by administering specific small molecule compounds that modify cellular parameters such as apoptosis resistance, oxidative stress resistance, and neurotrophic factor expression in retinal ganglion cells.
2Device complexity
If no effective drugs are used to inhibit Aβ aggregation, then the current treatment regimen is simple, but optic nerve damage progresses due to Aβ accumulation and aggregation
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of Aβ aggregation in glaucoma by using small molecule compounds that selectively bind to and inhibit Aβ aggregation. This extracts the harmful Aβ aggregation process from the complex glaucoma pathology and addresses it directly.
Solution Approach 2:
The patent employs composite therapeutic compounds that combine multiple functional moieties - including Aβ aggregation inhibition, antioxidant activity, and neurotrophic support - into single small molecule entities that can simultaneously address multiple pathological factors in glaucoma.
Data Source
AI summary
Disclosed is the use of a gold cluster or a gold cluster-containing substance in the preparation of a drug for preventing and/or treating glaucoma.